Cover Introduction ProSure Clinical Studies ... - Abbott Nutrition

A double blind randomized controlled trial on oral nutritional supplementation ofomega-3 fatty acids in non-small cell lung carcinomaCovervan der Meij BS, Languis JA, van Adrichem V, Spreeuwenberg MD, Smit EF, van Leeuwen PA Clin Nutr. 2008;3:111 (P193b)IntroductionProSureClinical StudiesSupportingPublicationsvan der Meij and colleagues conducted a double-blind, randomized,placebo-controlled trial in patients with stage III non-small cell lungcarcinoma who were randomized to receive either ProSure or acontrol supplement during 5 weeks of chemo-radiotherapy.ObjectiveTo assess the effect of an oral nutritional supplement enriched withomega-3 fatty acids on nutritional status in patients with non-smallcell lung carcinoma receiving chemo-radiotherapy.Study Design• Study Population: Patients with stage III non-small cell lungcarcinoma receiving chemo-radiotherapy (n = 40; ProSure = 20,control = 20)• Length of Study: 5 weeks• Intervention: 2 servings ProSure (240 mL/ serving) or isocaloricisonitrogenous controlOutcomes• Compared to the control group, the ProSure group had betterweight maintenance during weeks 1, 2, and 4 (1.2 kg, 1.4 kg, and1.8 kg, P < 0.05) and higher EORTC- QLQC30 physical functionscores at week 5 (P < 0.05).Study ConclusionsResults of this study underscore the beneficial effects of a highprotein,calorically-dense, low-fat nutritional supplement enriched withEPA (ProSure) on nutritional status and physical function in patientswith non-small cell lung carcinoma undergoing chemo-radiotherapy.EPA -eicosapentaenoic acid